A Trial to Assess TEV-56286 at Different Doses in Healthy Participants
- Study Title
- A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Escalating Dose Trial in Healthy Participants to Assess Pharmacokinetics, Safety, and Tolerability of TEV-56286 at Clinical and Supratherapeutic Doses
- Teva Identifier
- TV56286-PK-10202
- ClinicalTrials.gov Identifier
- NCT07674940
- Study Status
- Recruiting
- Trial Condition(s)
- Healthy Volunteers
- Interventions
- TEV-56286
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- 18 years to 60 years
- Trial Duration
- June 26, 2026 - January 22, 2027
- Phase
- Phase 1